Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis
Wirkung von Natrium-Glukose-Cotransporter-2-Inhibitoren auf Hämoglobin und Hämatokrit bei Herzinsuffizienz: systematische Übersichtsarbeit und Metaanalyse
ESC Heart Failure · 05.05.2026 · 13 (3)
DOI: 10.1093/eschf/xvag027 ↗Auf einen Blick
17 RCTs zeigen bei Herzinsuffizienz unter SGLT2-Inhibitoren höhere Hb- und Hct-Werte als unter Kontrolle. Die Effekte waren signifikant.
Fragestellung
Welchen Effekt haben SGLT2-Inhibitoren auf Hämoglobin und Hämatokrit bei Patient:innen mit Herzinsuffizienz?
Methode
Systematische Übersichtsarbeit und Metaanalyse von RCTs; Suche in PubMed, Web of Science, Cochrane Library und Embase bis April 2025; Random-effects-Modell, Subgruppen- und Metaregressionen.
Ergebnisse
17 RCTs mit 16 784 Teilnehmenden. Hb: MD 0,68 g/dl (95 %-KI 0,53–0,83; I2 = 39,7 %, P < .0001). Hct: MD 2,15 % (95 %-KI 1,73–2,57; I2 = 66,6 %, P < .0001).
Schlussfolgerung der Autor:innen
SGLT2-Inhibitoren erhöhen bei Patient:innen mit Herzinsuffizienz signifikant Hb und Hct. Weitere Forschung soll die klinische Bedeutung bei vorbestehender Anämie oder Nierenfunktionsstörung klären.
Kernaussagen
- Hb stieg unter SGLT2-Inhibitoren um MD 0,68 g/dl
- Hct stieg unter SGLT2-Inhibitoren um MD 2,15 %
- Kein Hinweis auf Publikationsbias
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift ESC Heart Failure, online erschienen am 19.01.2026. Verfasst von Shiva Armani Moghadam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Heart Failure, Sodium-Glucose Transporter 2 Inhibitors, Hemoglobins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The aim of this study is to evaluate the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on haemoglobin (Hb) and haematocrit (Hct) levels in patients with heart failure (HF). We systematically searched PubMed, Web of Science, Cochrane Library, and Embase for randomized controlled trials (RCTs) until April 2025. Changes in Hb and Hct were evaluated in HF patients treated with SGLT2 inhibitors compared to control subjects. A random-effects model was applied to calculate mean differences (MDs) with corresponding 95% confidence intervals (CIs). Subgroup analyses were performed across different SGLT2 inhibitors, follow-up durations, and types of control groups. Between-study heterogeneity was quantified using the I2 statistic, and meta-regression analyses were performed to explore the influence of baseline clinical characteristics on haematologic responses. Publication bias was evaluated using funnel plots and Egger’s test. Seventeen randomized controlled trials (RCTs) with 16 784 participants (mean age 68.65 years, 65.56% male) were included. Sodium-glucose cotransporter-2 inhibitors significantly increased Hb (MD = 0.68 g/dl, 95% CI: 0.53; 0.83, I2 = 39.7%, P-value <.0001) and Hct (MD = 2.15%, 95% CI: 1.73; 2.57, I2 = 66.6%, P-value < .0001) compared with controls. Subgroup analyses showed consistent benefits across individual SGLT2 inhibitors, duration of follow-up (≥6 months vs <6 months), and comparator type (placebo vs active control). There was no evidence of publication bias. Sodium-glucose cotransporter-2 inhibitors significantly increase levels of Hb and Hct in patients with HF. Further research is warranted to assess clinical significance in relation to Hb and Hct changes in patients with pre-existing anaemia or renal dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
- Research Center for Advanced Technologies in Cardiovascular Medicine, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran.
- Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
- Academic Clinical Lecturer, Newcastle University, Newcastle, UK.
ORCID-Profile: Mehrdad Mahalleh, Tor Biering-Sørensen, Kaveh Hosseini
Zitieren
APA
Armani Moghadam, S., Shahmohammadi, A., Salehi, K., Narimani-Javid, R., Soltani, P., Zafarmandi, S., Shafieyoun, M. H., Mahalleh, M., Ahmed, R., Bekfani, T., Biering-Sørensen, T., & Hosseini, K. (2026). Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis. ESC Heart Failure, 13(3). https://doi.org/10.1093/eschf/xvag027
Vancouver
Armani Moghadam S, Shahmohammadi A, Salehi K, Narimani-Javid R, Soltani P, Zafarmandi S, et al. Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis. ESC Heart Failure. 2026;13(3). doi:10.1093/eschf/xvag027
BibTeX
@article{ArmaniMoghadam2026,
author = {Armani Moghadam, Shiva and Shahmohammadi, Amirreza and Salehi, Keyvan and Narimani-Javid, Roozbeh and Soltani, Parnian and Zafarmandi, Sahar and Shafieyoun, Mohammad Hossein and Mahalleh, Mehrdad and Ahmed, Raheel and Bekfani, Tarek and Biering-Sørensen, Tor and Hosseini, Kaveh},
title = {Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis},
journal = {ESC Heart Failure},
year = {2026},
volume = {13},
number = {3},
doi = {10.1093/eschf/xvag027}
}
EUVIMED